An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape 1 , 2 – 3 , have
activity against diverse sarbecoviruses 4 , 5 , 6 – 7 , and be highly protective through viral …

Efficient therapeutic options are needed to control the spread of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) that has caused more than 922,000 fatalities as of 13 …

The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-binding
domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient plasma. Little …

The recent emergence of SARS-CoV-2 variants of concern 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 – 10
and the recurrent spillovers of coronaviruses 11 , 12 into the human population highlight the …

Understanding broadly neutralizing sarbecovirus antibody responses is key to developing
countermeasures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

In this study, a series of 10 quinoline analogues was evaluated for their in vitro antiviral activity
against a panel of alpha- and beta-coronaviruses, including the severe acute respiratory …

The recent emergence of SARS-CoV-2 variants of concern (VOC) and the recurrent spillovers
of coronaviruses in the human population highlight the need for broadly neutralizing …

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause late-onset, autosomal
dominant Parkinson's disease (PD). The clinical and neurochemical features of LRRK2-linked …

The efficacy of the standardized four-drug regimen (comprising isoniazid, rifampin, pyrazinamide,
and ethambutol) for the treatment of tuberculosis (TB) is menaced by the emergence of …

New drugs with new mechanisms of action are urgently required to tackle the global
tuberculosis epidemic. Following the FDA-approval of the ATP synthase inhibitor bedaquiline (…